Reports on the United States Food and Drug Administrations approval of arsenic trioxide for the treatment of patients with relapsed acute promyelotic leukemia. How the drug works by converting immature cancerous white blood cells into normal cells; Results of tests on patients; Adverse effects of ...
The prognosis for the T-ALL form of leukemia when relapsed is very poor, and new treatments are urgently required. The new therapy developed by the two institutions is a combination of drugs which was found to be effective in approximately one-third of patients. In the treatment of leukemia,...
BioModelAnalyzer, as recently reported in another Nature publication, Scientific Reports. In both cases, you can clearly see the impact this research already has on advancing our understanding of drug treatment in leukemia, and the potential it has to do the same for other common cancers. This ...
New Assay Could Revolutionize Detection and Treatment of Acute Myeloid Leukemia
Treatment of new cases of acute promyelocytic leukemia by arsenic trioxide. Blood 2004;104(11):396.Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, et al. Treatment of new cases of acute promyelocytic leukemia by arsenic trioxide without ATRA +/- chemotherapy ...
Although it is well recognized that there is a great need for newer and more effective chemotherapy for CNS leukemia, in the past 20 years no new effective intrathecal chemotherapy agents have been identified. Under this circumstance, one approach to improving CNS treatment is to explore the ...
Recent research has revealed that a ceramide-tamoxifen regimen may provide a promising new approach to treating Acute Myelogenous Leukemia (AML) by targeting the bioenergetic elements crucial to the survival of cancer cells. This innovative treatment aims to disrupt the metabolism of AML cells, potenti...
Acute myelocytic leukemia (AML). Credit: Unsplash/CC0 Public Domain New research published inScience Advancestoday conducted by researchers at Peter MacCallum Cancer Center show a new treatment for two challenging blood cancers could potentially help more patients than originally thought. Associate Profess...
The researchers have provided important proof-of-concept that T-cell receptor (TCR) T cells targeted to mutations shared between patients, can be an attractive therapeutic option in AML. "This provides hope that we can develop a new and effective treatment foracute myeloid leukemia, with likely ...
Professor Kamil Kranc, at The Institute of Cancer Research, London, said, "Therapy for acute myeloid leukemia has barely changed in several decades. There is a huge need to discover better treatments for this aggressive disease. We've shown for the first time that targeting the pathways that o...